Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: Survival and clinical outcome

Leukemia

Volumn 26, Issue 11, 2012, Pages 2439-2441

  Pardanani, A ^a   D'souza, A ^a   Knudson, R A ^a   Hanson, C A ^a   Ketterling, R P ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; HYBRID PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FIP1L1; UNCLASSIFIED DRUG;

CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE COURSE; EOSINOPHILIA; FOLLOW UP; GENE IDENTIFICATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LEUKEMIA; LONG TERM SURVIVAL; LYMPHATIC LEUKEMIA; MALIGNANT TRANSFORMATION; MYELOID LEUKEMIA; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; EOSINOPHILIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84869096442     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.162     Document Type: Letter

References (15)

1. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214. (Pubitemid 36359296)
2. Schaller JL, Burkland GA. Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001; 3: 9.
3. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577-1578. (Pubitemid 34621126)
4. Pardanani A, ReeDer T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorDers. Blood 2003; 101: 3391-3397. (Pubitemid 36857919)
5. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093-3096. (Pubitemid 37314742)
6. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660-4666. (Pubitemid 36857718)
7. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moDerate to severe eosinophilia. Blood 2004; 104: 3038-3045. (Pubitemid 39507117)
8. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: A phase-II study. Br J Haematol 2008; 143: 707-715.
9. Helbig G, Stella-Holowiecka B, Majewski M, Calbecka M, Gajkowska J, Klimkiewicz R et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA- expressing patients. Br J Haematol 2008; 141: 200-204. (Pubitemid 351406214)
10. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92: 1173-1179. (Pubitemid 350144174)
11. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 2007; 109: 4635-4640. (Pubitemid 46827752)
12. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA et al. FIP1L1-PDGFRA in eosinophilic disorDers: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30: 965-970. (Pubitemid 43831182)
13. Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA- positive chronic eosinophilic leukemia: Implications for optimal dosing. Blood 2007; 110: 3552-3556. (Pubitemid 350159620)
14. Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2011; 26: 162-164.
15. Fink SR, Belongie KJ, Paternoster SF, Smoley SA, Pardanani AD, Tefferi A et al. Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. Leuk Res 2009; 33: 843-846.